Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

CNS Neuroscience and Therapeutics

Volumn 19, Issue 5, 2013, Pages 302-306

  Preiningerova, Jana Lizrova ^a   Baumhackl, Ulf ^b   Csepany, Tunde ^c   Czaplinski, Adam ^d   Deisenhammer, Florian ^e   Derfuss, Tobias ^f   Fabjan, Tanja H ^g   Fazekas, Franz ^h   Fuchs, Siegrid ^h   Havrdova, Eva ^a   Ledinek, Alenka Horvath ⁱ   Illes, Zsolt ^j   Jazbec, Sasa Sega ⁱ   Klimova, Eleonora ^k   Komoly, Samuel ^j   Kurca, Egon ^l   Linnebank, Michael ^m   Lisy, Lubomir ⁿ   Mares, Jan ^o   Prochazkova, Lubica ^p   Csilla, Rozsa ^q   Szilasiova, Jarmila ^k   Stourac, Pavel ^r   Talab, Radomir ^s   Turcani, Peter ^t   Vachova, Marta ^u   Vecsei, Laszlo ^v   Vodusek, David ⁱ   Zapletalova, Olga ^w   Berger, Thomas ^e   more..

^a CHARLES UNIVERSITY   (Czech Republic)

^b Neurological Practice   (Australia)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF BASEL   (Switzerland)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF MARIBOR   (Slovenia)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j UNIVERSITY OF PÉCS   (Hungary)

^k University of Medicine   (Slovakia)

^l Jessenius School of Medicine   (Slovakia)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁿ Bratislava   (Slovakia)

^o PALACKÝ UNIVERSITY   (Czech Republic)

^p UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^q Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^r UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^s UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^t Faculty of Natural Sciences   (Slovakia)

^u Hospital of Teplice   (Czech Republic)

^v UNIVERSITY OF SZEGED   (Hungary)

^w UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

more..

Author keywords

Aminopyridines; Fampridine; Multiple sclerosis; Walking

Indexed keywords

4 AMINOPYRIDINE; BACLOFEN; BETA INTERFERON; PLACEBO;

ARTICLE; BALANCE DISORDER; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GENITAL SYSTEM DISEASE; HUMAN; MULTIPLE SCLEROSIS; NAUSEA; NERVE FIBER; PRACTICE GUIDELINE; SEIZURE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WALKING DIFFICULTY; WALKING SPEED;

EID: 84876794575     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12101     Document Type: Article

References (24)

1. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 2008;255:1354-1360.
2. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily function in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler 2008;14:988-991.
3. Hemmett L, Holmes J, Barnes M, Russel N. What drives quality of life in multiple sclerosis? QJM 2004;10:671-676.
4. Creange A, Serre I, Levasseur M, et al. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler 2007;13:220-223.
5. Stefoski D, Davis FA, Fault M, Schauf CL. 4 Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-77.
6. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. Neurol Sci 1983;60:353-362.
7. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis. FDA press release Jan 22, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm198463.html
8. European medicines agency, Public assessment report, June 23, 2011, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002097/WC500109957.pdf
9. Australian Public assessment report, June 2011 http://www.tga.gov.au/pdf/auspar/auspar-fampyra.pdf
10. Hayes K. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev 2004;10:295-316.
11. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-1059.
12. Goodman AD, Brown TR, Cohen JA, et al. Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-1141.
13. Goodman AD, Brown TR, Krupp LB, et al. Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: A randomized, double-blind, controlled trial. Lancet 2009;373:732-738.
14. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502.
15. Van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome measurement in multiple sclerosis: Detection of clinically relevant improvement. Mult Scler 2010;16:604-610.
16. Hoogervorst EL, Zwemmer JN, Jelles B, Polman CH, Uitdehaag BM. Multiple Sclerosis Impact Scale (MSIS-29): Relation to established measures of impairment and disability. Mult Scler 2004;10:569-574.
17. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: What is a reliable change? Neurology 2002;58:1294-1296.
18. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-36.
19. Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: Results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin 2012;28:49-56.
20. Hersh C, Rae-Grant A. Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Ther Adv Neurol Disord 2012;5:199-204.
21. Eriksson M, Ben-Menachem E, Andersen O. Epileptic Seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002;8:495-499.
22. De Gusmao CM, Ortega MR, Wallace DM. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2012;24:E47-E48.
23. Rissmiller DJ, Campo T. Extended-release bupropion induces grand mal seizures. J Am Osteopath Assoc 2007;107:441-442.
24. Jara M, Henney HR, Wessel T, et al. Dalfampridine extended release tablets: One year of post marketing safety experience in the United States. Mult Scler 2011;17:S216-S217 (P508).